Transforming Treatment: Tris Pharma is a biopharmaceutical company committed to delivering effective and unique therapies for patients around the world suffering from ADHD, pain, addiction and other diseases of the central nervous system.
We are using our industry-leading capabilities and innovative, proprietary technologies to develop and market therapies that uniquely solve some of the most difficult treatment challenges in these diseases and conditions.
Over the past two decades, we’ve established a foundation of exceptional technologies, differentiated investigational therapies pushing the boundaries of innovation, and market-leading medicines that are making a tangible difference in patient outcomes. Our successful partnerships have amplified our reach and impact, and we’ve assembled a team of experienced people dedicated to delivering transformative solutions. By leveraging the breadth and depth of this comprehensive foundation, we are making significant strides in improving the lives of patients globally.
We’ve also been a long-time leader in delivering high-quality, patient-friendly generic medicines across many therapeutic categories. Learn more about our generics portfolio and capabilities at www.CranburyPharma.com.
A Company Built
for Patients
- Founded in 2000
- Headquartered in Central New Jersey
- Privately held
- 500+ employees
- 9+ approved New Drug Applications (NDAs)
- Rich pipeline of investigational therapies across multiple indications
- Multiple global partnerships
Delivering Differently
Our proprietary, innovative LiquiXR® platform has powered the development of more than a dozen Tris therapies and programs, as well as numerous successful global development partnerships.
LiquiXR® enables us to create high-quality, unique, patient-friendly solutions that deliver maximum therapeutic benefit.
Medicines
Our comprehensive and expanding portfolio of leading medicines offers a range of treatment options to enhance care and experience for both adults and children with the disorder.
Pipeline
We have a pipeline of six investigational therapies with potential to help patients living with multiple disorders, including chronic and acute pain, addiction, narcolepsy and spasticity.
Partnerships
We license our LiquiXR® technology to companies around the world to bring innovative treatments to patients and caregivers.
People
Tris’ diverse workforce of more than 500 employees is collectively inspired by our exceptional leadership, a culture of care and four core values: believe you/we can, lead by example, listen to understand, and keep things simple and practical. Explore our culture here.